Your one-stop Caco-2 solution
24 or 96 transwell insert plates seeded with 21 days differentiated and polarized Caco-2 cells. The reference in vitro technique to evaluate intestinal permeability in novel orally administered compounds, according to leading regulatory agencies.
|KRECE-CCR01||CacoReady 24 Transwell|
|KRECE-CCR02||CacoReady 24 Well (without transwell)|
|KRECE-CCR04||CacoReady 24 Well (individual transwell)|
|KRECE-CCR50||CacoReady 96 Transwell|
|KRECE-CCR51||CacoReady 96 Well (without transwell)|
CacoReady in the Literature
- Yeste, S., et al. (2020). Preliminary in Vitro Assessment of the Potential of EST64454, a Sigma-1 Receptor Antagonist, for Pharmacokinetic Drug–Drug Interactions. Biological and Pharmaceutical Bulletin, 2020 Vol. 43:1 p. 68-76.
- Aubets J, Jansat J-M, Salva M, et al. (2019). No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) drug transporter. Pharmacol Res Perspect. 2019;e00540.
- Guardiola et al. (2018). Targeted Covalent Inhibition of Prolyl Oligopeptidase (POP): Discovery of Sulfonylfluoride Peptidomimetics. Cell Chemical Biology 25, 1031–1037.
- Kenzaoui, B.H., Vilà, M., Juillerat-Jeanneret, L. (2012). Evaluation of uptake and transport of cationic and anionic ultrasmall iron oxide nanoparticles by human colon cells. Int J Nanomedicine. 2012; 7: 1275–1286. doi: 10.2147/IJN.S26865.
Pankiewicz, Piotr, et al. “Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists.” Pharmaceuticals 14.8 (2021): 704.
A secreting mucus intestinal barrier
24 transwell insert plates seeded with 21 days differentiated and polarized Caco-2 and HT-29 (human goblet) cells. An in vitro intestinal absorption evaluation of drug targets in a barrier physiologically closer to the intestinal epithelium.
|KRECE-CCG01||CacoGoblet 24 Transwell|
|KRECE-CCG02||CacoGoblet 24 (individual transwell)|
CacoGoblet in the literature
- Servi, B., Ranzini, F. (2017). Protective efficacy of antidiarrheal agents in a permeability model of Escherichia coli-infected CacoGoblet cells. Future Microbiology, vol. 12, no. 16. https://doi.org/10.2217/fmb-2016-0195
- Fraile, B., et al. (2017). Xyloglucan, hibiscus and propolis for the prevention of urinary tract infections: results of in vitro studies. Future Microbiology, vol. 12, no. 8. https://doi.org/10.2217/fmb-2017-0015
An alternative cellular model based on MDCKII cells
24 and 96 transwell insert plates cultured with 12 days differentiated MDCKII parental line cells. A reference in vitro model to evaluate passive permeation and specific receptor mediated transport of new compounds.
|KRECE-CTR01||PreadyPort-CTRL (24 Transwell)|
|KRECE-CTR50||PreadyPort-CTRL (96 Transwell)|
|KRECE-MDR01||PreadyPort-MDR1 (24 Transwell)|
|KRECE-MDR02||PreadyPort-MDR1/CTRL 1:1 (24 Transwell)|
|KRECE-MDR50||PreadyPort-MDR1 (96 Transwell)|
|KRECE-MDR51||PreadyPort-MDR1/CTRL 1:1 (96 Transwell)|
PreadyPort in the literature
- Miyamoto, R., et al. (2019). The Impact of Endogenous Breast Cancer Resistance Protein on Human P-Glycoprotein-Mediated Transport Assays Using LLC-PK1 Cells Transfected With Human P-Glycoprotein. Journal of Pharmaceutical Sciences, Vol. 108, Issue 3, pp. 1085-1089. https://doi.org/10.1016/j.xphs.2018.10.012
- Aubets, J., Jansat, J-M., Salva, M., et al. (2019). No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) drug transporter. Pharmacol Res Perspect. 2019;e00540. DOI: 10.1002/prp2.540
ReadyCell ready-to-use cell monolayer kits benefits
- No in-house cell culture maintenance nor cell licensing costs
- Shipments worldwide to any location at room temperature thanks to our patented technology
- High flexibility
- High reproducibility within and between manufacturing batches
- Cell-based assays ready-to-use
- Highly predictive and useful in the in vitro to in vivo progression
- Technical support during the assay and in bio-analytics
It is well known that food intake changes luminal conditions (e.g. pH, motility, microbiota,…) in the stomach and the small intestine, modifying drugs bioavailability. Food-drug interactions are one of the major challenges for oral-administered drugs, even more so if considering the growing use of food supplements and functional foods.
The endothelial cells that conform the BBB limit the passage of blood circulating endogenous substrates and larger molecules to the brain. This intrinsic protective role is also a major hurdle for reasearchers developing drugs for Central Nervous System (CNS) disorders.
Cell-based in vitro models are suitable to evaluate human phisiology optimizing research. This review introduce reference models to evaluate gastrointestinal metabolism.